VERASTEM INC. news, videos and press releases
For more news please use our advanced search feature.
VERASTEM INC. - More news...
VERASTEM INC. - More news...
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Verastem Oncology Announces Reverse Stock Split
- Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
- Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
- Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
- Verastem Oncology to Participate in Upcoming Investor Conferences
- New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
- Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
- Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
- Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
- Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Appoints Rob Gagnon to Board of Directors
- Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Appoints Anil Kapur to Board of Directors
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
- Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)